Ivantis Raises US$46.5 Million in Series B Financing
13 January 2014

Ivantis, developer of the novel Hydrus® Microstent device designed to lower eye pressure for laucoma patients, announced today that it secured an additional US$14 MM from Vertex Ventures and GBS Ventures in the final close of its Series B financing. This additional US$14 MM takes the total Series B to US$46.5 MM, making it one of the largest medical device financings of the past year.

Established in 2007, Ivantis, Inc. is a medical device company based in California. It designs, develops and commercializes new technologies to treat eye disease .

For more details, please visit Ivantis News/Press Releases

"$100m fund to help start-ups survive ‘valley of death’ gap" by Grace Chng
11 January 2014

Vertex announced the launch of a new S$100 million fund to help local start-ups in Singapore. This fund aims to help start-ups grow and survive the “valley of death” finance gap in the early stages of a start-up. The fund will primarily invest in companies in the infocomm technology and healthcare sectors with investment size ranging from US$1 million to US$10 million for each investment.

In an interview with The Straits Times, Vertex CEO Mr Chua Kee Lock said: “We are looking for start-ups with disruptive and innovative businesses that can become Singapore’s next billion-dollar companies.”

Apart from capital funding, Mr Chua said Vertex also aims to provide “non-financial advice like mentoring founders, finding talents, making business connections and regional and global marketing”.

Local entrepreneurs and start-up founders welcomed Vertex’s new funding initiative and felt that it would benefit start-ups beyond the seed stage. (Source: The Straits Times)